• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can Antidepressants Prolong Survival in Cancer Patients?

Can Antidepressants Prolong Survival in Cancer Patients?

May 21, 2021
Paul Barkopoulos, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Paul Barkopoulos, MD. Dr. Barkopoulos has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review Of: Shoval G et al, Depress Anxiety 2019;36(10):921–929

Many cancer patients experience depression, especially those with poor prognoses. Compared with euthymic patients, depressed cancer patients are less adherent to their cytotoxic medications, and this poor adherence can worsen their long-term survival. Yet surprisingly, some studies have reported a higher mortality rate among cancer patients taking antidepressants—but might confounding factors account for this finding (eg, patients with worse prognoses are more likely to be depressed and therefore to be placed on antidepressants)?

This large (n = 42,075) retrospective cohort study controlled for several confounding factors to get a better understanding of the relationship between antidepressant use and mortality. Using an Israeli national health services database, the authors extracted data on patients who were diagnosed with cancer and purchased an antidepressant prescription within the 4-year study period (2008–2012). Patients were further divided into subgroups based on antidepressant adherence, ranging from non-adherent to highly adherent. Adherence was defined as the number of months with actual filled prescriptions divided by the number of months when an antidepressant was prescribed.

An initial analysis indicated an increase in mortality with antidepressant adherence, but also revealed that older and sicker patients tended to be the most adherent, leading to an over-representation of mortality in the adherent group.

A subsequent analysis, adjusting for such factors, showed the opposite: Patients who were adherent to their antidepressant lived significantly longer than patients who were minimally adherent (< 20% adherent) or non-adherent. The mortality rate among patients with the highest antidepressant adherence (> 80% adherent) was 20% lower, over the study period, compared to the non-adherent or minimally adherent group. Subgroup analyses showed this adherence benefit remained regardless of cancer type, including lung, prostate, breast, and colon cancer.

CHPR’s Take
This large retrospective study found that antidepressant adherence was associated with improved survival in people with cancer. Whether this is due to greater adherence to cancer treatment or some other reason remains unclear. The study should further our resolve to treat depression and anxiety in cancer patients, and to encourage patients to not miss doses of their antidepressants.
Hospital Psychiatry
KEYWORDS adherence cancer citalopram depression escitalopram fluoxetine mortality paroxetine prozac serotonin-specific-reuptake-inhibitors-ssris sertraline ssris
    Paul Barkopoulos, MD.

    QT Intervals in Psychiatric Practice

    More from this author
    www.thecarlatreport.com
    Issue Date: May 21, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Capacity Assessments, CHPR, April/May/June 2021
    Finally, Effective Treatments for Tardive Dyskinesia
    Decisional Capacity
    Capacity Assessment in Pregnant Patients
    Suvorexant May Prevent Delirium in Hospitalized Patients
    SSRIs and Intracerebral Hemorrhage Risk
    Can Antidepressants Prolong Survival in Cancer Patients?
    Hyperprolactinemia: Effective Treatment With Aripiprazole
    Note From the Editor-in-Chief
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.